蔡淵欽(Tsai, Yuan-Chin) 副教授

Email
yuanchin@tmu.edu.tw
現   職
癌症生物學與藥物研發研究所 副教授

學經歷

學 歷

畢業學校與學位[修業時間]
Rutgers UniversityPharmacology 博士
2002/09~2008/02
陽明大學生化 碩士
1996/09~1998/06
臺灣大學農業化學 學士
1992/09~1996/06

本校學術經歷

任職單位與職稱[起迄時間]
癌症生物學與藥物研發研究所副教授
2018/12/01~
癌症生物學與藥物研發博士學位學程副教授
2018/02/01~2018/11/30
癌症生物學與藥物研發博士學位學程助理教授
2013/08/01~2018/01/31

本校兼職教學行政經歷

服務單位與職稱[起迄時間]
癌症生物學與藥物研發博士學位學程副教授
2019/01/01 ~

其它經歷

任職單位與職稱[起迄時間]
princeton UniversityPostdoc
2009/09~2013/04

專長與研究領域

學門領域
學術專長
昹源蘋楊
Western blotting
煦赽硈
molecular cloning
?婉璵硈
cell culture

論文著作

清冊下載


1. 2020 Yu-Ching Fan, Wei-Yu Chen, Kuan-Der Lee,Yuan-Chin Tsai. Tumor-infiltrating Leukocytes Suppress Local Inflammation Via Interleukin-1 Receptor Antagonist in a Syngeneic Prostate Cancer Model . Biology(Basel) .2020 ;(9)

2. 2018 Tsai YC,Zeng T,Abou-Kheir W,Yeh HL,Yin JJ,Lee YC, Chen WY, Liu YN. Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer . Molecular Cancer .2018 ;(17):42-42

3. 2018 Tsai YC,Chen WY,Abou-Kheir W,Zeng T,Yin JJ,Bahmad H, Lee YC, Liu YN. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2 . BBA - Molecular Basis of Disease .2018

4. 2018 Zhong WB,Tsai YC,Chin LH,Tseng JH,Tang LW,Horng S, Fan YC, Hsu SP. A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model. . Int J Mol Sci. .2018 ;(19)

5. 2017 Chen MC,Tsai YC,Tseng JH,Liou JJ,Horng S,Wen HC, Wen HC, Fan YC, Zhong WB, Hsu SP. Simvastatin Inhibits Cell Proliferation and Migration in Human Anaplastic Thyroid Cancer. . International Journal of Molecular Sciences .2017 ;(18)

6. 2017 Tsai YC,Chen WY,Tsai HY,Siu MK,Yin JJ,Huang J, and Liu YN. Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6 . Cancer letters .2017 ;(384):1-8

7. 2017 Man KS,Chen WY,Tsai HY,Chen HY,Yin JJ,Chen CL Tsai YC, Liu YN. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer . Prostate cancer and prostatic diseases .2017

8. 2017 Chen WY,Tsai YC,Siu MK,Yeh HL,Chen CL,Yin YY, Huang J, and Liu YN. Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis . Oncogene .2017

9. 2017 Chen WY,Tsai YC,Yeh HL,Suau F,Jiang KC,Shao AN, Huang J, Liu YN. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer. . Science Signaling .2017 ;(10)

10. 2017 Tsai YC,Liu YN. New ideas in preventing castration-resistant prostate cancer. . Oncotarget .2017

11. 2016 Siu MK,Suau F,Chen WY,Tsai YC,Tsai HY,Yeh HL, Liu YN. KLF4 functions as an activator of the androgen receptor through reciprocal feedback. . Oncogenesis .2016 ;(5):e282

12. 2015 Rowles DL,Tsai YC,Greco TM,Lin AE,Li M,Yeh J, Cristea IM. The DNA methyltransferase DNMT3A associates with viral proteins and impacts HSV-1 infection. . Proteomics .2015

13. 2015 Siu MK,Tsai YC,Chang YS,Yin JJ,Suau F,Chen WY, Liu YN. Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway. . Oncogene .2015 ;(34):4767-4776

14. 2014 Tsai YC,Greco TM,Cristea IM. Sirtuin 7 plays a role in ribosome biogenesis and protein synthesis . Mol Cell Proteomics. .2014 ;(13):73-83

15. 2013 Tsai YC,Greco TM,Boonmee A,Miteva Y,Cristea IM. Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. . Mol Cell Proteomics .2013

16. 2011 Lin RK,Zhou N,Lyu YL,Tsai YC,Lu CH,Kerrigan J, Chen YT, Guan Z, Hsieh TS, Liu LF. Dietary isothiocyanate-induced apoptosis via thiol modification of DNA topoisomerase IIα. . J Biol Chem .2011

17. 2010 Azarova AM,Lin RK,Tsai YC,Liu LF,Lin CP,Lyu YL. Genistein induces topoisomerase IIbeta- and proteasome-mediated DNA sequence rearrangements: Implications in infant leukemia. . Biochem Biophys Res Commun .2010

18. 2009 Tsai YC,Qi H,Lin CP,Lin RK,Kerrgan JE,Rzuczek SG, LaVoie EJ, Rice JE, Pilch DS, Lyu YL, Liu LF. A G-quadruplex stabilizer induces M-phase cell cycle arrest. . J Biol Che .2009

19. 2009 Feng W,Satyanarayana M,Tsai YC,Liu AA,Liu LF,LaVoie EJ. 12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents. . Bioorg Med Chem .2009

20. 2009 Feng W,Satyanarayana M,Tsai YC,Liu AA,Liu LF,LaVoie EJ. Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide. . Eur J Med Chem .2009

21. 2009 Sharma L,Tsai YC,Liu AA,Liu LF,LaVoie EJ. Cytotoxicity and TOP1-targeting activity of 8- and 9-amino derivatives of 5-butyl- and 5-(2-N,N-dimethylamino)ethyl-5H-dibenzo[c,h][1,6]naphthyridin-6-ones. . Eur J Med Chem .2009

22. 2008 Feng W,Satyanarayana M,Cheng L,Liu A,Tsai YC,Liu LF, LaVoie EJ. Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents. . Bioorg Med Chem. .2008

23. 2008 Feng W,Satyanarayana M,Tsai YC,Liu AA,Liu LF,LaVoie EJ. 11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents. . Bioorg Med Chem .2008

24. 2008 Satyanarayana M,Feng W,Cheng L,Liu AA,Tsai YC,Liu LF, LaVoie EJ. Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31). . Bioorg Med Chem .2008

研究計畫

計畫名稱
108 免疫療法開發計畫(III)-發展胰臟癌免疫治療
補助單位
智合精準醫學科技股份有限公司

計畫名稱
107 研究去勢療法之後的前列腺癌病變及發展阻斷發炎的癌症免疫療法
補助單位
科技部

計畫名稱
106 免疫療法開發計畫(Ⅱ)
補助單位
智合生醫科學股份有限公司

計畫名稱
106 探討microRNA96在轉化生長因子β導致的癌症演進過程的角色(3/3)
補助單位
科技部

計畫名稱
105 探討microRNA96在轉化生長因子β導致的癌症演進過程的角色(2/3)
補助單位
科技部

計畫名稱
105 探討microRNA96在轉化生長因子β導致的癌症演進過程的角色(2/3)
補助單位

計畫名稱
104 免疫療法開發計畫
補助單位
智合生醫科學股份有限公司

計畫名稱
104 免疫療法開發計畫
補助單位
智合生醫科學股份有限公司

計畫名稱
104 探討microRNA96在轉化生長因子β導致的癌症演進過程的角色(1/3)
補助單位
科技部

計畫名稱
104 探討microRNA96在轉化生長因子β導致的癌症演進過程的角色(1/3)
補助單位
科技部

計畫名稱
102 研究SIRT7在癌症生物學的角色
補助單位
行政院國家科學委員會

計畫名稱
102 研究SIRT7在癌症生物學的角色
補助單位
科技部

計畫名稱
102 TMU102-AE1-B30
補助單位
臺北醫學大學新聘教師計畫